Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research note released on Thursday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance AKTX opened at $3.20 on Thursday. The business has a 50 day moving average price of $3.58 and a 200 […]

Leave a Reply

Your email address will not be published.

Previous post ATA Creativity Global (NASDAQ:AACG) Now Covered by StockNews.com
Next post Forestar Group (NYSE:FOR) Upgraded by StockNews.com to “Buy”